Published by Josh White on 11th September 2020
(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.
URL: http://www.digitallook.com/dl/news/story/31165506/...